| Literature DB >> 35784312 |
Abstract
Purpose: Although respiratory diseases (RD) are rapidly becoming a global health issue due to their high mortality and prevalence, there are limitations to the currently available treatments. Acupuncture has been recognized to mitigate many diseases by reducing inflammation and modulating cytokines. However, no systematic analysis has been performed to examine the effects of acupuncture on RD. We aimed to evaluate the effects of acupuncture on rodent animal models of RD.Entities:
Keywords: acupuncture; animal models; inflammatory cytokines; meta-analysis; respiratory diseases
Mesh:
Substances:
Year: 2022 PMID: 35784312 PMCID: PMC9241441 DOI: 10.3389/fimmu.2022.878463
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1Flowchart of the Study.
Quality Assessment.
| Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiang et al., 2011 ( | ✓ | ✓ | ✓ | 3 | |||||||
| Geng et al., 2013 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 7 | |||
| Zhang et al., 2014 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
| Li et al., 2016 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
| Nurwati et al., 2015 ( | ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||
| Song et al., 2015 ( | ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||
| Wei et al., 2017 ( | ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||
| Wang et al., 2017 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
| Dong et al., 2018 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
| Dong et al., 2019 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
| Zhang et al., 2018 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
| Dhar et al., 2019 ( | ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||
| Huang et al., 2019 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 7 | |||
| Zhou et al., 2019 ( | ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||
| Cui et al., 2021 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 7 | |||
| Lou et al., 2020 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
| Tang et al., 2021 ( | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
| Zhang et al., 2021 ( | ✓ | ✓ | ✓ | ✓ | ✓ | 5 |
Q1, publication in a peer-reviewed journal; Q2, statements describing control of temperature; Q3, random allocation to treatment or control; Q4, blinded building of model; Q5, use of animals with hypertension or diabetes; Q6, blinded assessment of outcome; Q7, use of anesthetic without marked intrinsic properties; Q8, sample size calculation; Q9, compliance with animal welfare regulations; Q10, declared any potential conflict of interest.
Study Characteristics.
| Animal Species | Disease Model | Intervention | Specimen | Cytokines | |
|---|---|---|---|---|---|
| Jiang et al., 2011 ( | Mouse | ALS induced lung inflammation | EA | Lung tissue | TNF-ɑ, IL-6 |
| Geng et al., 2013 ( | Rat | COPD | EA | BALF | TNF-ɑ, IL-1β |
| Zhang et al., 2014 ( | Rat | COPD | EA | BALF | TNF-ɑ, IL-1β |
| Li et al., 2016 ( | Rat | COPD | MA | BALF | TNF-ɑ, IL-8 |
| Nurwati et al., 2015 ( | Mouse | Asthma | MA | Plasma | IL-17 |
| Song et al., 2015 ( | Rat | Thermal injury induced lung inflammation | EA | Plasma | TNF-ɑ, IL-1β, |
| Wei et al., 2017 ( | Mouse | Asthma | MA | Serum | TNF-ɑ, IL-1β, |
| Wang et al., 2017 ( | Rat | CPB induced lung inflammation | EA | Lung tissue | TNF-ɑ, IL-1β |
| Dong et al., 2018 ( | Mouse | Asthma | MA | Serum | TNF-ɑ, IL-1β, |
| Dong et al., 2019 ( | Mouse | Asthma | MA | Serum | IL-5, IL-10, |
| Zhang et al., 2018 ( | Rat | COPD | EA | BALF, Lung tissue | TNF-ɑ, IL-6 |
| Dhar et al., 2019 ( | Rat | CPB induced lung inflammation | EA | Lung tissue | TNF-ɑ, IL-1β, |
| Huang et al., 2019 ( | Rat | CPB induced lung inflammation | EA | BALF, Serum | IL-1β |
| Zhou et al., 2019 ( | Mouse | Chronic sinusitis | EA | Nasal tissue | IL-10, IFN-γ |
| Cui et al., 2021 ( | Mouse | Asthma | MA | Serum | IL-5, IL-9, IL-13, |
| Lou et al., 2020 ( | Rat | Limb ischemia/reperfusion induced lung inflammation | EA | Lung tissue | TNF-ɑ, IL-1, IL-6, |
| Tang et al., 2021 ( | Mouse | Asthma | MA | BALF, Serum | IL-4, IL-5, IL-13, IL-17A |
| Zhang et al., 2021 ( | Rat | COPD | EA | BALF | TNF-ɑ, IL-10, |
ALS, amyotrophic lateral sclerosis; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; EA, electroacupuncture; MA, manual acupuncture; BALF, bronchoalveolar lavage fluid.
Figure 2Forest Plot of Pro-/Anti-inflammatory Cytokines. (A) Pro-inflammatory Cytokines (B) Anti-inflammatory Cytokines.
Figure 3Forest Plot of Th cell-specific Cytokines. (A) Th1-specific Cytokines (B) Th2-specific Cytokines (C) Th17-specific Cytokines.
Results of Lung Function Tests.
| Results | Lung Function Tests | |
|---|---|---|
| Jiang et al., 2011 ( | N/A | |
| Jiang et al., 2011 ( | Improved | RL ↓, Cdyn ↑ |
| Zhang et al., 2014 ( | Improved | FEV0.1 ↑, FEV0.3 ↑, FEV0.1/FVC ↑ FEV0.3/FVC ↑ |
| Li et al., 2016 ( | Improved | IC ↑, PEF ↑, MV ↑ |
| Nurwati et al., 2015 ( | N/A | |
| Song et al., 2015 ( | N/A | |
| Wei et al., 2017 ( | Improved | RL ↓, Cdyn ↑ |
| Wang et al., 2017 ( | N/A | |
| Dong et al., 2018 ( | Improved | RL ↓, Cdyn ↑ |
| Dong et al., 2019 ( | Improved | RL ↓, Cdyn ↑ |
| Zhang et al., 2018 ( | Improved | FEV0.1 ↑, FEV0.3 ↑, FEV0.1/FVC ↑ FEV0.3/FVC ↑ |
| Dhar et al., 2019 ( | N/A | |
| Huang et al., 2019 ( | N/A | |
| Zhou et al., 2019 ( | N/A | |
| Cui et al., 2021 ( | Improved | RL ↓, Cdyn ↑ |
| Lou et al., 2020 ( | N/A | |
| Tang et al., 2021 ( | Improved | RL ↓, Cdyn ↑ |
| Zhang et al., 2021 ( | Improved | RL ↓, Cdyn ↑ |
N/A, not applicable; RL, lung resistance; Cdyn, dynamic compliance; FEV0.1, forced expiratory volume in 0.1s; FEV0.3, forced expiratory volume in 0.3s; FVC, Forced vital capacity; IC, inspiratory capacity; PEF, peak expiratory flow; MV, minute volume.